Skip to main content

Suven Life Sciences spurts on stake sale buzz

Suven Life Sciences was locked at upper limit of 20% at Rs 46.55 on BSE on reports that firm was in talks with two private equity firms to dilute up to 10% stake.

On BSE, 66.18 lakh shares of the scrip were traded. The stock had an average daily volume of 1.76 lakh shares on BSE in past one quarter.
The scrip had touched a low of Rs 38.85 so far during the day. The stock had hit a 52-week high of Rs 46.90 on 20 August 2007 and a 52-week low of Rs 27.08 on 20 December 2006.
The scrip had outperformed the market in the one month to 17 December 2007, adding 19.38% as against the Sensex's 2.22% decline. It had also underperformed the market in the past three months, gaining 5.58% against the Sensex's 22.93% rise.
The small-cap firm has an equity capital of Rs 11.56 crore. Face value per share is Rs 1.
At the current price of Rs 46.55, the scrip trades at a PE multiple of 116.37, based on Q2 September 2007 annualised EPS of Rs 0.40.
Suven Life Sciences reportedly plans to raise up to $30 million by March 2008 through an issue of shares to private equity and a convertible bond issue to fund its drug discovery programme.
According to reports, the money raised through the issue would be used to fund the development of Suven's experimental drug compound SUVN-502, which enters the initial phase of clinical trials in January 2008. SUVN-502 is being developed as a possible treatment for Alzheimer's Schizophrenia and cognition-related disorders.
A part of the proceeds would also be used to develop its drug discovery infrastructure in Hyderabad to strengthen its collaborative research services, the report added.
Suven Life Sciences’ net profit fell 53.4% to Rs 1.16 crore on 0.1% decline in sales to Rs 27.84 crore in Q2 September 2007 over Q2 September 2006.
Suven Life Sciences’ principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the USA, Europe, Asia and India.

Popular posts from this blog

Bio-fuel has top investors powered up

23RD ,JUNE India's fortune-hunters believe their new-found love for biofuel will pay off. India's well-known investors who are known for their Midas touch have spotted an opportunity in bio-fuel, betting big on ethanol, bio-mass and even bio-fuel equipment makers in India and other parts of the globe. Billionaires Rakesh Jhunjhunwala, C Sivasankaran, Vinod Khosla, founder of Sun Microsystems, and Nemish Shah, the media-shy joint partner of Enam Financial Services, are investing in bio-fuel makers quietly, expecting that bio-fuel will have a big play in the coming years as the world looks for a viable alternative to the fast depleting oil reserves. Jhunjhunwala, who is known for his ability to spot a multi-bagger at a very early stage, recently invested in Hyderabad-based bio-fuel firm Nandan Biometrics.He is also a 10 per cent stakeholder in Praj Industries, which is a bio-fuel technology provider…

up to 8,500% return in 5 years! Investors made a killing in these 30 smallcap stocks

U By Rahul Oberoi, ETMarkets.com | Updated: Dec 01, 2017, 04.06 PM IST Post a Comment
Efficiency pays in the long run. Among the top smallcap plays on Dalal Street, 30 companies with stable return on equity (RoE) and return on capital employed (RoCE) have surged up to 8,500 per cent over the past five years.

All these companies had a debt-to-equity ratio of less than 1 and have been maintaining RoE and RoCE of over 20 per cent since 2012-13.

Avanti Feeds emerged the chart topper, with an 8,527 per cent gain to Rs 2,596.60 as of November 28 from Rs 30.10 ..


ovember 28 from Rs 30.10 on November 27, 2012. The company’s return on equity for FY17, FY16, FY15, FY14 and FY13 stood at 42.65 per cent, 46.21 per cent, 52.41 per cent, 45.79 per cent and 27.60 per cent, respectively. Avanti also managed to achieve a return on capital employed of over 50 per cent in last four years. Its RoCE stood at 28.59 per cent inRoE measures net income earned for every rupee of shareholder funds, while…

5 dark-horse picks

Kwadrat/shutterstock.com Kwadrat/shutterstock.com
If you are a conservative investor, using the mutual fund route is the best way to invest in stocks. But if you are game for some excitement, you might want to dabble directly in stocks, especially small-cap stocks. Stocks that are smaller in size, in terms of market capitalisation, carry higher risk. The reasons are — one, lower traded volume increases price volatility, two, information is usually scarce on these companies, three, business risk is higher since many of these companies are dependent on a single product and four, governance risk is also higher in these stocks. That said, small-cap stocks have the capacity to deliver far greater returns when compared to large-cap stocks. Sample this: there were 16 stocks with market cap more than ₹50,000 crore in January 2009. These stocks delivered an average return of 138 per cent in the last eight years but 4 out of every 10 stocks in this group delivered negative returns. On the ot…